"The progress made on the pandemic and seasonal influenza programs in such a short time reflects the priority and importance of this development program for both companies," said Dr. Robert V. House, president and chief scientific officer of DVC. "By combining Baxter's technology with DVC's biologics life-cycle and contract management expertise, the team has made great progress in advancing these two influenza vaccine candidates."
"The funding validates the potential for these cell culture vaccine candidates," said Kim Bush, president of Baxter's Vaccines business. "We look forward to continuing to develop influenza vaccines that may make a meaningful scientific and medical contribution to those using the vaccines and for government pandemic planning."
Baxter International Inc., through its subsidiaries, assists health-care professionals and their patients with the treatment of complex medical conditions, including cancer, hemophilia, immune disorders, kidney disease and trauma. The company applies its expertise in medical devices, pharmaceuticals and biotechnology to make a meaningful difference in patients' lives.
DVC provides end-to-end program management and solutions for the development of biopharmaceutical products. For more information, visit DVC's Web site at http://www.csc.com/dvc.
DVC is part of CSC's North American Public Sector business unit's
Government Health Services Division. CSC's expertise in providing health
services to government agencies has grown over the last five decades to
offer commercial best practices integrated to meet federal, state and local
|SOURCE Computer Sciences Corporation|
Copyright©2007 PR Newswire.
All rights reserved